الرسائل الموجهة للمختصين الصحيين
| المنتج | التاريخ | معلومات السلامة | المرفقات |
|---|---|---|---|
| Gilenya® - Fingolimod |
Hemophagocytic syndrome (HPS) reported in patients treated with Gilenya®. |
||
| Neupogen® - Filgrastim |
Risk of capillary leak syndrome in patients with cancer. |
||
| ZOFRAN® - Ondansetron |
Updated information on posology for intravenous use and dose dependant QT interval prolongation. |
||
| Diane-35® - Ethinylestradiol/Cyproterne |
Risk of Thromboembolism. |
||
| MabThera® - Rituximab |
The management of hepatitis B reactivation in patients treated with MabThera®. CLICK HERE |
||
| LARIAM® - Mefloquine |
Important Safety Update of Prescribing Information for LARIAM®. |
||
| VOTRIENT® - Pazopanib |
Important change to frequency of Serum liver test monitoring for hepatotoxicity. |
||
| TASIGNA® - Nilotinib |
Updated information regarding the possible risk of developing atherosclerosis-related diseases with the use of TASIGNA®. |
||
| DUROGESIC® -Fentanyl |
Introduction of New Warning-Serontonin syndrome may occur under co-administration with serotonergic drugs. |
||
| Fenatnyl‐Janssen ® - Fentanyl |
Fenatnyl‐Janssen Introduction of New Warning ‐ Serontonin syndrome may occur under co‐administration with serotonergic drugs. |
